Skip to main content

Table 1 Demographic data from all patients participating in the study.

From: L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study

Case Age (years) Sex Subtype (DSM-IV) Duration of illness (years) Antipsychotic treatment, dosage
1 56 M Schizophrenia, undifferentiated 9 Risperdal consta 25 mg/2w
2 23 F Schizophrenia, undifferentiated 3 Leponex 700 mg/day,
3 29 M Schizophrenia, unspecified 8 Risperdal 2 mg/day, Abilify 25 mg/day
4 45 M Schizophrenia, paranoid 6 NA
5 35 M Schizophrenia, unspecified 11 Leponex 200 mg/day, Abilify 15 mg/day
6 54 M Schizophrenia, undifferentiated 29 Zyprexa 15 mg/day
7 51 M Schizophrenia, paranoid 23 Leponex 100 mg/day, Abilify 10 mg/day
8 56 M Schizophrenia, undifferentiated > 15 Zyprexa 10 mg/day, Cisordinol 140 mg inj 1/4w
9 - - - - -
10 39 F Schizophrenia, paranoid 8 Risperdal 4 mg/day
11 44 M Schizophrenia, unspecified 26 Leponex 800 mg/day, Abilify 10 mg/day
  1. Case 9 dropped out due to difficulties ingesting the study medicine.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us